Our publications
Publications 2022
Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E; on behalf of Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics 2022, 11, 751. https://doi.org/10.3390/antibiotics11060751
Publications 2021
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G; Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. J Glob Antimicrob Resist. 2022 Mar;28:102-107. doi: 10.1016/j.jgar.2021.12.016.
Kresken M, Pfeifer Y, Werner G. Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae. GMS Infect Dis 2021; 9:Doc08 (20211221). https://doi.org/10.3205/id000077
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G; Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalized patients in Germany: occurrence, characteristics, and susceptibility to dalbavancin. J Glob Antimicrob Resist. 2021 Dec 24:S2213-7165(21)00289-7. https://doi.org/10.1016/j.jgar.2021.12.016
Weber RE, Fleige C, Layer F, Neumann B, Kresken M, Werner, G. Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium. Antibiotics 2021, 10(8), 915. https://doi.org/10.3390/antibiotics10080915
Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG. In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. J Global Antimicrob Resist. 2021;25: 337–338
Gill CM, Kresken M, Seifert H, Nicolau DP. Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort. Microb Drug Resist. 20121; 27: 1243–1248. https://doi.org/10.1089/mdr.2020.0476
Publications 2020
Gatermann S, Hamprecht A, Kresken M.
Die veränderte Definition von SIR bei Empfindlichkeitstestungen nach EUCAST.
Krankenhaushygiene up2date 2020; 15: 395–403
Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK. The VRE study group. Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat 53 (2020) 100732
Kresken M, Pfeifer Y, Werner G. Temocillin susceptibility in Enterobacterales with an ESBL/AmpC-phenotype. Int J Antimicrob Agents. 2020; In Press, Journal Pre-proof, Available online 7 November 2020.
Kresken M, Korte-Berwanger M, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Int J Antimicrob Agents. 2020; 56:106128.
Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2020;75(9):2616–2621. https://doi.org/10.1093/jac/dkaa208folgende
Gröschel MI, Meehan CJ, Barilar I, Diricks M, Gonzaga A, Steglich M, Conchillo-Solé O, Scherer IC, Mamat U, Luz CF, De Bruyne K, Utpatel C, Yero D, Gibert I, Daura X, Kampmeier S, Rahman NA, Kresken M, van der Werf TS, Alio I, Streit WR, Zhou K, Schwartz T, Rossen JWA, Farhat MR, Schaible UE, Nübel U, Rupp J, Steinmann J, Niemann S, Kohl TA. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nat Commun. 2020 Apr 27;11(1):2044. doi: 10.1038/s41467-020-15123-0.
Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H; German Carbapenem Resistance Study Group. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int J Antimicrob Agents. 2020; 55(6): 105959 doi: 10.1016/j.ijantimicag.2020.105959.
Bodmann KF, Kresken M, Grabein B, Dohmen PM, Wilke M. Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics. GMS Infect Dis 2020; 8:Doc19 (20200326).
Kresken M, Grabein B, Becker K, Straube E, Wichelhaus TA, Willinger B. Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Microbiology. GMS Infect Dis 2020; 8:Doc18 (20200326)